Medical imaging such as CT, MRI and PET scans can be used to make a diagnosis or prognosis, select therapy, monitor responses to therapy and yield pharmacokinetic information about drugs. EORTC’s Imaging research aims to establish and maintain the scientific and clinical value of advanced imaging. We develop specific analytical, review and quality control procedures in the context of EORTC clinical trials.
- QuIC-ConCePT (Quantitative Imaging in Cancer: Connecting Cellular Processes with Therapy )
- TRISTAN (Translational Imaging Methods in Drug Safety Assessment )
- EORTC RP 1106: A three-step study on the feasibility and prognostic value of rCBV in patients with GBM.
(project leader: M. Smits) Three steps project:
- Technical evaluation of acquisition a standardized protocol, centralized data storage, quality assurance.
- Compare quantification to select and test post-processing tools, to standardize methodology for rCBV measurements and to assess inter- and intra- reader variability.
- Prognostic value of rCBV to predict patient outcome.
A publication on repeatability and reproducibility of relative cerebral blood volume measurement in recurrent glioma will be submitted soon.
- EORTC RP 1547 (PICRIB): Platform for imaging in clinical research in Brussels
(project leader: J. Vandemeulebroucke)
PICRIB is a clinical imaging platform that will enable the interoperability of the Brussels university hospitals and facilitate the patient mobility. EORTC is the WP7 lead, and provides guidance regarding standards applicable for imaging used in clinical trial e.g. images acquisition and interpretation, inter-institution quality assurance/ quality control.
Hôpital Européen Georges Pompidou
L. Bidaut - Lincoln, GB
Chair of Radiomics subcommittee
University of Lincoln
C. Caramella - Villejuif, FR
Chair of Immuno-Imaging subcommittee
N. deSouza - Sutton, GB
Chair of Bone- and Oligomets subcommittee
Royal Marsden Hospital Sutton
Impact of the COVID-19 Crisis on Imaging in Oncological Trials
Evaluation of diffusion-weighted MRI and (18F) fluorothymidine-PET biomarkers for early response assessment in patients with operable non-small cell lung cancer treated with neoadjuvant chemotherapy
Repeatability of quantitative 18F-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group
Strategies and Technical Challenges for Imaging Oligometastatic Disease: Recommendations from the EORTC Imaging Group.